

RADIATION ONCOLOGY CONFERENCE

FEB
12-14
2026

Vincent Stabile Research Building (SRB) at Magnolia Campus
12902 USF Magnolia Drive, Tampa, FL 33612

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$
$$\frac{dB}{dt} = k_1 A \left(\frac{A}{S}\right) \left(1 - \frac{B}{M_1}\right) - dB$$
$$\frac{dH}{dt} = k_2 H \left(1 - \frac{H}{M_2}\right)$$



KEYNOTE SPEAKERS:

Dr. Lou Harrison
Dr. Wally Curran

Dr. Arnab Chakravarti
Dr. Xiaoying Liang

Fast,
Consistent,
Personalized

Dose+

AI-Guided Plan Optimization For Radiotherapy Planning

*CE marked and FDA 510K cleared

MVISION

www.mvision.ai

RAD formation

 **ChartCheck Adaptive™**

The First Fully Integrated Platform
Combining Adaptive Assessment
with In-Vivo Monitoring

“Radformation’s Offline Adaptive Assessment solution will offer our clinicians clearer insights and efficiency in assessing daily changes and evaluating their cumulative impact on the entire course of treatment...”

- Trent Aland | Executive Manager, Clinical Care at Icon Group

See What’s Next in Adaptive Care →



WELCOME



Welcome to the Radiation Oncology Conference (ROC) at Moffitt Cancer Center.

It is our pleasure to welcome you to ROC 2026, a conference created to bring together leaders, innovators, and collaborators from across the radiation oncology community. We are honored to host clinicians, scientists, medical physicists, radiation therapists, dosimetrists, trainees, and industry partners who share a common commitment to advancing cancer care through innovation, research, and collaboration.

ROC was designed as a dynamic forum to explore the rapidly evolving landscape of radiation oncology. Throughout the conference, participants will engage in plenary sessions, hands-on workshops, multidisciplinary tumor boards, and interactive discussions highlighting advances in adaptive radiation therapy, precision imaging, artificial intelligence, biomarker-guided treatment strategies, and emerging technologies that are shaping the future of our field.

As Moffitt Cancer Center continues to expand its clinical and research initiatives, including the growth of our proton therapy program in Pasco County, Florida. We remain focused on translating innovation into meaningful clinical impact. This conference reflects our commitment to fostering collaboration across disciplines and institutions, and to accelerating progress through shared expertise and partnership.

We extend our sincere gratitude to our distinguished speakers, sponsors, and planning committees whose contributions have made this conference possible.



Most importantly, we thank you—our attendees—for your participation, engagement, and dedication to advancing the science and practice of radiation oncology.

We hope ROC 2026 provides an inspiring, educational, and collaborative experience, and we look forward to the meaningful conversations and partnerships that will emerge from this gathering.

Kosj Yamoah, MD, PhD
Executive ROC Sponsor
Chair, Department of Radiation Oncology
Moffitt Cancer Center & Research Institute

Eduardo Moros, PhD
Executive ROC Sponsor
Chief, Medical Physics
Moffitt Cancer Center & Research Institute



GETTING TO MOFFITT

ARRIVE ON UNIVERSITY OF SOUTH FLORIDA CAMPUS

Navigate to
Moffitt Cancer Center:

STABILE RESEARCH BUILDING
12902 MAGNOLIA DR
TAMPA FL, 33612

Limited parking is available
at **Moffitt Gold Garage** and
Laurel Garage for self-park

Pay to Park is available
through the ParkMobile App
in designated areas



MOFFITT CANCER CENTER - MAGNOLIA CAMPUS


If being dropped off, follow signs for
MOFFITT GOLD VALET
STABILE RESEARCH

Building is right next to drop off point

Enter building to find
REGISTRATION DESK



VENUE MAP



Check in will be at Registration Desk with Moffitt team. Exhibitor Badges will be provided and will be needed for dining and learning areas.

Exhibitor Tables will be assigned and provided upon check in at registration to ensure accurate table count.

If arriving at a different time than designated set-up on Thursday, February 12th, please alert Moffitt team prior to arrival to ensure exhibitor table is allocated.



Edge radiosurgery system

Expanding the Edge of Radiosurgery

Visit <https://cancercare.siemens-healthineers.com/edge> to learn more.



REGISTRATION AND PARTICIPATION

When checking in for the conference, you will be assigned a unique QR code at registration, which you will be given with your badge. Please keep this QR code available, as it will be used to verify your attendance of sessions for the event per the guidelines of the accrediting bodies. You will also be asked to verify which accrediting body you are pursuing credits for.

Participation will be monitored digitally for credit awarding. Digital check-in will be required at the beginning of the first session of the conference, after lunch, and after completion of the last session. Check-in will be performed in the auditorium where all sessions are held, and attendees will scan their QR code upon entry with assistance from a member of the conference team.

After completion of the event, certificates of completion will be available for pick-up at the registration table. This certificate will serve as your official record of attendance and should be used to claim continuing education credits with the appropriate accrediting body.



BLUE EARTH
D I A G N O S T I C S
A Bracco Company

**EMPOWERING
THE EVOLUTION
OF CARE
FOR PATIENTS
WITH CANCER**

Innovative solutions that transform clinical management and patient care

Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on developing and delivering **innovative molecular imaging technologies that inform diagnosis and treatment decisions for optimized patient outcomes.**

Formed in 2014, the company's success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics' expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology.

Learn more about Blue Earth Diagnostics:

www.BlueEarthDiagnostics.com



PROGRAM

Thursday - February 12, 2026

9:00 am	Registration
10:00 am	Surface Guided Radiation Therapy
11:00 am	Triggered Imaging for Intrafraction Motion Management in Prostate and Spine SBRT
12:00 pm	Lunch
1:00 pm	MRI Guided Adaptive RT With a MR-LINAC
2:00 pm	Ultra-High Dose Rate (UHDR) Electron for FLASH and iRAI Studies
3:00 pm	Break
3:30 pm	CT-Guided Online Adaptive Radiotherapy With Ethos <i>Bladder and Thoracic Cases</i>
4:30 pm	Spatially Fractionated Radiotherapy: Clinical Indications and Treatment Planning
5:30 pm	Refining and Automating Head and Neck Treatment Planning: A Journey Through Time



Friday - February 13, 2026

7:00 am	Registration and Breakfast
8:00 am	Radiation Oncology Vision at Moffitt Cancer Center
8:30 am	Keynote Speaker Lou Harrison, MD
9:30 am	Genomic Radiation Treatment Planning
10:15 am	Break
10:45 am	Evolving Role of Virtual Reality in Radiation Oncology
11:30 am	Habitat Escalated Adaptive Therapy (HEAT) in Soft Tissue Sarcoma
12:15 pm	Lunch
Multidisciplinary Clinic / Tumor Board Genitourinary, Head and Neck	
1:30 pm	GU
1:30 pm	H&N
2:30 pm	Cardiac Dose and Radiotherapy: Getting to the Heart of the Matter
3:15 pm	Keynote Speaker Arnab Chakravarti, MD
4:15 pm	Break
4:45 pm	Contemporaneous Errors in Radiation Therapy and Mitigating Strategies
5:30 pm	A system for tracking and Minimizing the Effects of Medical Errors in Radiation Oncology
6:15 pm	HIV and Cancer
7:15 pm	Social Event RVSP Needed

Saturday - February 14, 2026

7:00 am	Registration and Breakfast
7:50 am	Welcome and Introduction
8:00 am	Optimizing Palliative Radiotherapy
8:45 am	Keynote Speaker Wally Curran, MD
9:45 am	Personalizing Treatment with Adaptive Radiotherapy: Threading the Needle
10:30 am	Break
11:00 am	The Role of Radiotherapy in the Era of Cellular Therapy
11:45 am	Keynote Speaker Xiaoying Liang, PhD
12:45 pm	Lunch
1:45 pm	How Will AI Change the Daily Radiation Oncology Landscape in the Next 5 Years
2:30 pm	Practical Applications of Cherenkov Radiation Imaging in the Clinic
3:15 pm	Closing Remarks

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$

$$\frac{dB}{dt} = k_1 A \left(\frac{A}{S}\right) \left(1 - \frac{B}{M_1}\right) - dB$$

$$\frac{dH}{dt} = k_2 H \left(1 - \frac{H}{M_2}\right)$$



CONFERENCE ACCREDITATION

This multi-seminar event will address a range of topics across multiple solid tumor disease sites, including:

Discussing novel methods to further personalize radiation therapy, reduce treatment-related toxicity, and enhance patient quality of life.

Reviewing currently available technologies for standard treatment across multiple disease sites, with a focus on improving quality assurance and mitigating errors.

ACCME >>>>>>

The number of CME credits that will be offered as part of this conference will adhere to the guidelines provided by the ACCME. 60 minutes of participation in a certified educational activity will equal one credit and will be broken into 15-minute intervals as outlined below.

The credits offered will include one session covering HIV/AIDS and two sessions covering medical errors.

Minutes	Credit
15	0.25
30	0.5
45	0.75
60	1.0
75	1.25
90	1.5
105	1.75
120	2.0

ASRT >>>>>>

Per the guidelines of the ASRT, the number of credits offered for multiday seminars will be awarded based on the following scale:

IMPORTANT: Per the guidelines of the ASRT, participants seeking to claim credit will need to attend all seminars in one day to receive all credits for that day. Absence of any single session during a seminar day will result in the voiding of credit for all other sessions of that day, regardless of attendance.

Minutes	Credit
15-29	0.25
30-49	0.5
50-62	1.0
63-74	1.25
75-87	1.5
88-99	1.75
100-112	2.0

Hosting case-based sessions that highlight a comprehensive, multidisciplinary approach to cancer evaluation and management.

Engaging attendees in discussions on the continued expansion of the field of radiation oncology and the role of emerging and existing technologies in driving future growth.



CAMPEP >>>>>

Per the guidelines of the CAMPEP, the number of MPCEC hours for an approved educational activity will be determined by the CAMPEP CEC Committee or a Subcommittee appointed for this purpose. In general, one MPCEC hour will be granted for each hour of approved educational activity.

Minutes	Credit
30	0.5
60	1.0
90	1.5
120	2.0

MDCB >>>>>>

Per the guidelines of the MDCB for multisession Conferences, the number of credits that will be awarded for participants will be based on the following guidelines.

Minutes	Credit
15-29	0.25
30-49	0.5
50-74	1.0
75-89	1.25
90-104	1.5
105-119	1.75
>120	Credit assessed will be based on 1 CE per 60 minutes and rounded down to the nearest 1/4 hour for any CE equal to or less than .25 credit.

KEYNOTE SPEAKERS



Arnab Chakravarti, MD, Chair of the Department of Radiation Oncology at The Ohio State University College of Medicine

Dr. Arnab Chakravarti is a Professor and Chair of the Department of Radiation Oncology at The Ohio State University College of Medicine, where he also holds the Klotz Chair in Cancer Research. He directs Ohio State's Proton Therapy Center, the first of its kind in central Ohio, and is a pioneer in proton therapy and FLASH radiotherapy. A thought leader in particle therapy, he serves on the Steering Committee of PT-COG and the International Scientific Advisory Board of FRPT. His research focuses on overcoming resistance to cancer therapies and developing novel radiosensitizers, with more than 200 publications in leading journals. Dr. Chakravarti previously served on the Harvard faculty and helped launch the first hospital-based proton therapy center at Mass General.



Wally Curran, MD, Chief of Piedmont Oncology Institute

Dr. Walter J. Curran Jr. is a radiation oncologist specializing in malignant brain tumors and locally advanced lung cancer. He joined Piedmont Healthcare in 2023 after serving as global chief medical officer of GenesisCare and executive director of Winship Cancer Institute at Emory University. Dr. Curran is Professor Emeritus at Emory and a Georgia Research Alliance Eminent Scholar Emeritus. A fellow of the American College of Radiology and the American Society of Clinical Oncology, he has led landmark trials and helped define the global staging system for malignant glioma. His honors include the ASTRO Gold Medal and honorary memberships in several international societies.



Louis Harrison, MD, CEO, President & Co-Founder at MyCareGorithm, LLC.


Dr. Lou Harrison is President, CEO, and Co-Founder of MyCareGorithm, LLC. A graduate of Duke University and SUNY Downstate Medical Center, he completed his Radiation Oncology training at Yale. Dr. Harrison previously held leadership roles at Memorial Sloan Kettering, Mount Sinai Continuum Cancer Centers of New York, and Moffitt Cancer Center, where he remains Chair Emeritus. He has served as President of ASTRO, the American Brachytherapy Society, and the International Society of Intraoperative Radiation Therapy. A recognized leader in head and neck cancer and sarcoma research, he has authored over 300 publications and is the senior editor of *Head and Neck Cancer: A Multidisciplinary Approach*. His numerous honors include the ASTRO Gold Medal for lifetime contributions to clinical care, research, and education.



Xiaoying Liang, PhD, Professor, Radiation Oncology Medical Physicist at Mayo Clinic

Dr. Xiaoying Liang, PhD, DABR, is a Professor of Medical Physics and Consultant in the Department of Radiation Oncology at Mayo Clinic Florida. She specializes in advancing particle therapy, proton therapy optimization, and medical physics education. Dr. Liang has held academic and clinical leadership positions at the University of Florida and University of Arkansas while also delivering 100 peer-reviewed publications. She is an Associate Editor for major journals including *Medical Physics* and *JACMP*, and serves on multiple committees within AAPM, ASTRO, and NRG Oncology. Her research has significantly contributed to improving proton therapy delivery, treatment quality, and patient outcomes.

**RaySearch
Laboratories**



[CODING] ENERGY TO #END_CANCER;

At RaySearch Laboratories, we transform energy into intelligence.

Innovative yet refined radiotherapy software has always been at the core of our technology. Through advanced algorithms, we shape emergent therapeutical energy into optimized cancer care.

Our software solutions are more than just lines of code — they empower energy to fight cancer.

SYSTEMS



RayStation

Comprehensive cancer treatment planning



RayCare

The next generation oncology information system



RayIntelligence

Advancing cancer treatment through machine learning

OUR SOLUTIONS

Machine Learning

Intelligent treatment planning

Liver Ablation*

Image-guided planning for interventional radiology

DrugLog*

Control in every compound, confidence in every patient



RayMigrate

Transfer your pinnacle data with ease



RayStation

Planning and evaluation for pre-clinical research



RayPlan

Fast, efficient, and straightforward to use

*This product is in an ongoing development phase and not for sale in the USA and Canada. RaySearch products are subject to regulatory clearance in some markets.

PROGRAM CHAIRS



Kosj Yamoah, MD, PhD

Radiation Oncology Department Chair

Dr. Kosj Yamoah is a board-certified radiation oncologist specializing in genitourinary cancers and a physician-scientist in cancer health disparities. He serves as Chair of Radiation Oncology at Moffitt Cancer Center, Director of Radiation Oncology Health Disparities Research, and Senior Professor at USF's Morsani College of Medicine. Dr. Yamoah leads a global lab studying gene-specific drivers of aggressive prostate cancer in men of African descent. A nationally recognized leader in prostate cancer disparities research, he is advancing Moffitt's Radiation Oncology program to improve health equity and patient outcomes.



Eduardo Moros, PhD

Chief of Medical Physics

Dr. Eduardo G. Moros is a distinguished faculty member and Chief of Medical Physics for the Departments of Radiation Oncology and Diagnostic Imaging at Moffitt Cancer Center. He collaborates closely with scientists and clinicians to apply physics and engineering to biomedical research, promoting translational studies that enhance patient care and safety. Actively engaged in professional societies, national research initiatives, and editorial service, Dr. Moros also champions the growth of medical physics through education, institutional partnerships, and contributions to the scientific community.



CLINICAL ACCURACY

Pinpoint micrometastases at the earliest signs in a broad range of patients.¹

HIGH-QUALITY IMAGES

Trust high-quality images across vital regions, with scan time ≤ 30 minutes.²⁻⁵

RELIABLE DISTRIBUTION

Order directly from more than 220 radiopharmacies with flexible scheduling and on-time delivery.^{4,6-9}

END-TO-END SUPPORT

Dedicated industry-leading support for your practice through the Telix Network of Support.



Learn more about Illuccix by visiting illuccixhcp.com or scanning the QR Code.

INDICATIONS AND USAGE

ILLUCXIX, after radiolabeling with Ga-68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- With suspected metastasis who are candidates for initial definitive therapy
- With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic product

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

Risk for Misinterpretation

Image interpretation errors can occur with ILLUCXIX PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. Gallium Ga-68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's Disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Imaging Prior to Initial Definitive or Suspected Recurrence Therapy

The performance of ILLUCXIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of ILLUCXIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score.

RADIATION RISKS

Gallium Ga-68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS

The safety of gallium Ga-68 gozetotide was evaluated in 960 patients in the PSMA-PreRPand PSMA-BCR studies, each receiving one dose of gallium Ga-68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of $<1\%$.

In the VISION study, 1003 patients received one dose of gallium Ga-68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at $\geq 0.5\%$ in patients with metastatic prostate cancer who received gallium Ga-68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%).

Adverse reactions occurring at a rate of $< 0.5\%$ in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills.

Injection site pain has been identified during postapproval use of ILLUCXIX.

DRUG INTERACTIONS


Androgen deprivation therapy and other therapies targeting the androgen pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga-68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga-68 gozetotide PET has not been established.

Please note that this information is not comprehensive. Please see the Full Prescribing Information.

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit [MedWatch at www.fda.gov/medwatch](http://MedWatch.fda.gov/medwatch) or call 1-800-FDA-1088. You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-638 or emailingpharmacovigilance@telixpharma.com.

References: 1. Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information. 2. Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of ⁶⁸Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. *JAMA Oncol.* 2021;7(11):1635-1642. 3. Hofman MS, Lavrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet.* 2020;395(10231):1208-1216. 4. Velikyan I. ⁶⁸Ga-based radiopharmaceuticals: production and application relationship. *Molecules.* 2015;20(7):12913-12943. 5. Data on File. Isotope Decay Rates. Telix Pharmaceuticals. 2022. 6. Massat MB. Nuclear medicine prepares for greater ⁶⁸Ga demand. *Appl Radiol.* 2021;50(2):30-31. <https://appliedradiology.com/articles/nuclear-medicine-prepares-for-greater-ga-68-demand>. Accessed June 9, 2023. 7. Data on File. Activated Sites. Telix Pharmaceuticals. 2023. 8. Data on File. Distribution Metrics. Telix Pharmaceuticals. 2023. 9. Data on File. Delivery. Telix Pharmaceuticals. 2022.

The Telix Pharmaceuticals and the Illuccix® name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates. © 2026 Telix Pharmaceuticals Ltd. All rights reserved. US-ILL-2500003 1.2026



“This new technology allows us to extend our clinical and research expertise into **proton therapy**, as we seek to continually provide the best possible patient outcomes.”

Patrick Hwu, MD,
President and CEO of Moffitt Cancer Center



ExacTrac Dynamic Surface

More than just the surface

ExacTrac Dynamic Surface[®] is an SGRT patient tracking system that offers streamlined workflows and department-wide standardization.



Explore more:
brainlab.com/exactrac-dynamic-surface

WORKSHOP SPEAKERS

Conference Workshops



Kujtim Latifi, PhD, Associate Member Physicist

Dr. Latifi is an Associate Member of the Departments of Radiation Oncology and Machine Learning and Co-Director of Adaptive Therapy at Moffitt Cancer Center. He specializes in imaging applications for radiation oncology, with a strong focus on the clinical integration of advanced imaging technologies. His work centers on the development and implementation of imaging-driven software solutions to improve treatment accuracy, efficiency, and clinical workflows in radiation therapy. Through his efforts, Dr. Latifi aims to enhance precision medicine approaches and improve overall patient care.



Andrew Lee, RTT, Manager Radiation Therapy

Andrew Lee is the Manager of Radiation Oncology Technical Operations, where he supports workflow optimization and operational excellence in the delivery of radiation oncology care. Originally from Australia, he holds a Bachelor of Science in Healthcare Management from Rasmussen University and is committed to advancing efficient, patient-centered clinical operations.



Lou Nardella, MS, Physics Clinical Specialty Coordinator

Lou Nardella is a clinical medical physicist in Radiation Oncology with over 33 years of experience in both community and academic hospital settings. His work focuses on patient safety, treatment quality, and practical clinical problem-solving, with particular expertise in implementing new technologies. His interests include the use of IGRT and real-time tracking to ensure accurate treatment delivery in complex cases.



Amber Nelsen, RTT, Radiation Therapy - Supervisor

With more than 19 years at Moffitt Cancer Center, Amber has built a distinguished career in radiation therapy with a strong commitment to patient-centered care. She currently serves as Supervisor of the Radiation Therapy Department at the Wesley Chapel location, where she oversees daily operations and supports a highly dedicated clinical team. Her work emphasizes the highest standards of safety, quality, and compassionate care. She is passionate about collaboration, continuous improvement in clinical practice, and mentoring staff to achieve optimal patient outcomes.

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$

$$dB = \dots$$



Daniel Opp, PhD, Clinical Physicist

Dan Opp, PhD, received his doctorate in Applied Physics from the University of South Florida in 2009. He joined the Department of Radiation Oncology at Moffitt Cancer Center as a medical physicist following his graduation. His areas of expertise include CNS treatment planning, clinical automation, linear accelerator quality assurance, and treatment planning system commissioning. His professional interests focus on software-based quality assurance, secondary dose verification, scripting and workflow automation, and Surface Guided Radiation Therapy.



Jose Penagaricano, MD, Senior Member - Radiation Oncology

Dr. Penagaricano completed his residency at Beth Israel Medical Center in Manhattan, New York. Prior to joining Moffitt Cancer Center, he was a tenured Professor in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences, where he served as Medical Director of the Radiosurgery Program and the Medical Physics Residency Program. He specializes in central nervous system (CNS) tumors and palliative care. A pioneer in the clinical implementation of IMRT, his work continues to focus on robust photon treatment plan optimization for highly modulated beams. His current research interests include spatially fractionated radiation therapy (GRID and SBRT-PATHY) and robust optimization strategies.



Gage Redler, PhD, Associate Member Physicist

Dr. Redler is an associate member and medical physicist in the Department of Radiation Oncology at Moffitt Cancer Center. In addition to his clinical duties, Dr. Redler conducts research focusing on leveraging advanced imaging and radiotherapy technologies/techniques to enhance precision and more effectively guide personalized radiation therapy.



Mary Vargas, CMD, Senior Dosimetrist

Mary Vargas, RTT, CMD is a Medical Dosimetrist at Moffitt Cancer Center in Tampa, Florida, where she specializes in radiation treatment planning for neurological and hematological malignancies. She earned her bachelor's degree in medical Dosimetry from John Patrick University. Her clinical interests include total body irradiation (TBI), GRID therapy, SBRT-PATHY, and pulsed reduced dose rate (PRDR) planning. She is committed to advancing precision and innovation in radiation therapy to support optimal patient outcomes.

CONFERENCE SPEAKERS >>>>>>>

Conference Presentations



Kamran Ahmed, MD, Radiation Therapy - Supervisor

Dr. Kamran Ahmed is the Vice Chair for Clinical Research for Moffitt Cancer Center's Department of Radiation Oncology and the Section Chief for the institution's Breast Radiotherapy Service. In addition to his clinical care, Dr. Ahmed pursues several research interests including the synergism between combinations of immunologic and targeted agents with radiation therapy to improve clinical outcomes as well as the management of brain metastases and leptomeningeal disease with novel therapeutics and radiation therapy. Dr. Ahmed has published over 100 peer-reviewed manuscripts and has presented his research nationally and internationally.



Jacqueline Andreozzi, PhD, Assistant Member Physicist

Dr. Jacqueline Andreozzi is a medical physicist and Chair of the Radiation Oncology Quality Improvement Committee at Moffitt Cancer Center and professor for the Morsani College of Medicine and Department of Physics at the University of South Florida. She also serves as Associate Director for the Moffitt Therapy Physics Residency and USF-Moffitt Medical Physics Graduate Programs. In addition to her clinical duties, Dr. Andreozzi also participates as a research investigator on several initiatives looking into quantifying dose variation and application to improve overall treatment for various methods.



Thomas Dilling, MD, Senior Member - Radiation Oncology

Dr. Thomas Dilling is the director of the Thoracic Section for the Department of Radiation Oncology at Moffitt Cancer Center where he utilizes his clinical expertise in stereotactic body radiotherapy, motion management issues, theragnostic imaging, and normal tissue dose constraints to help monitor radiotherapeutic treatment for thoracic malignancies. Dr. Dilling's research interests focus on the use of "Big Data" and artificial intelligence to generate novel insights into patient treatment and toxicity resulting in the curation of a radiotherapy database, among the largest and most complex in the world, consisting of thousands of Moffitt patients who have received lung targeted radiotherapy.



Dipesh Niraula, PhD, Applied Research Scientist

Dipesh Niraula is an applied research scientist working in Dr. Issam El Naqa's research group. He received his Ph.D. and M.S. in Theoretical and Computational Device Physics from the University of Toledo. He worked in Dr. El Naqa's lab as a post-doctoral researcher in the Department of Radiation Oncology at the University of Michigan and then in the Department of Machine Learning at Moffitt Cancer Center. During his post-doctoral research, he developed ARCLiDS, a clinical decision support software for AI-assisted decision-making in adaptive RT and developed a hybrid quantum deep reinforcement learning framework for decision-making in adaptive RT. ARCLiDS is capable of recognizing dose-response, predicting RT outcome, and recommending optimal dose adaptation. Currently he is engaged in a Human-AI interaction type experiment for evaluating ARCLiDS.

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$

$$dB = \dots$$



Vladimir Feygelman, PhD, Senior Member Physicist

Dr. Feygelman is an Associate Member of the Department of Radiation Oncology at Moffitt Cancer Center. He is an experienced board-certified clinical physicist, with research interests centered on radiation dosimetry and quality assurance of complex dynamic treatments. This includes evaluation and improvement of dosimetry systems, particularly diode arrays, clinical comparisons, applications to different dose modulation techniques, and 4D dosimetry. Over the span of his career, Dr. Feygelman has over 60 peer-reviewed publications.



Nick Figura, MD, Assistant Member Heme Radiation Oncologist

Dr. Nicholas Figura is an Assistant Member in the Department of Radiation Oncology. Dr. Figura will be located at the Moffitt partnership site at Morton Plant Hospital in Clearwater, working with Dr. Ronica Nanda and Dr. Roberto Diaz. Dr. Figura received his MD from the University of South Florida, Morsani College of Medicine. He recently completed a Radiation Oncology Residency at Moffitt Cancer Center/University of South Florida, where he also served as Chief Resident. Dr. Figura's clinical interests include the use of definitive radiotherapy in the treatment of head and neck, thoracic, gastrointestinal, and hematologic malignancies as well as the use of palliative radiotherapy for oligometastatic disease. His primary research focuses on the use of radiotherapy in novel clinical settings to ultimately improve patient outcomes, such as 1) combining immunotherapy and radiation in the treatment of oligometastatic disease, 2) incorporating radiotherapy as a bridging treatment strategy for patients undergoing CAR T-cell therapy, and 3) exploring the potential role of noninvasive cardiac ablation using stereotactic radiotherapy for refractory cardiac arrhythmias.



Sarah Hoffe, MD, Senior Member - Radiation Oncology

Dr. Sarah Hoffe is the Interim Chair of Gastrointestinal Medical Oncology at Moffitt Cancer Center and the first radiation oncologist at Moffitt to be selected as Physician of the Year. At Moffitt, she works closely with her colleagues to develop new treatments and employ advanced radiation therapy techniques such as IMRT, 3D-CRT, SBRT, radioembolization, and IGRT using endoscopically implanted fiducial markers. In addition to GI cancers and radiation oncology, Dr. Hoffe is also interested in the integration of novel patient engagement technologies that will improve the patient's experience, such as piloting novel virtual reality tools. Nationally, she is the Director of eContouring at ASTRO, part of the advisory board for the Contemporary Radiation Oncology Journal, and a contributor to the Up to Date Online educational site, having co-authored the section on bone metastases.



Peter Johnstone, MD, Senior Member - Radiation Oncology

At Moffitt Cancer Center, Dr. Johnstone has served in several prominent roles including Clinical Director and Vice Chair of the Department of Radiation Oncology. Dr. Johnstone has clinical interest in pediatrics, and genitourinary malignancies and sarcomas. His recent clinical trials have involved acupuncture as symptom control in cancer patients, and his recent publications have dealt with the use of proton radiotherapy in children. Outside of Moffitt, Dr. Johnstone has held several leadership positions including Director of the Survivorship Program at the Emory Winship Cancer Institute, Chair and William A. Mitchell Professor of Radiation Oncology at Indiana University School of Medicine, President and Chief Executive Officer of the IU Health Proton Therapy Center, Director of the Indiana University cyclotron, President of the Society for Integrative Oncology, and President of the American Radium Society. He has received several honors including the American Radium Society's gold medal for his outstanding contributions and service in oncology.

CONFERENCE SPEAKERS >>>>>>>



Emily Keit, MD, Radiation Oncology

Dr. Emily Keit attended college at the University of Nebraska at where she studied biotechnology and chemistry then pursued medical school at University of Nebraska Medical Center. She completed her preliminary internal medicine year with University of South Florida and Moffitt Cancer Center. Dr. Keit has continued her mentorship at Moffitt with the Department of Radiation Oncology, her clinical interests focusing on the role of radiotherapy in metastatic disease with a particular emphasis on expanding access to palliative and oligometastatic treatment.



Kedar Kirtane, MD, Associate Member – Medical Oncology

Dr. Kirtane is an Assistant Member in the Department of Head and Neck-Endocrine Oncology and Medical Director for Solid Tumor Cellular Therapy. Dr. Kirtane received his MD degree from The University of Florida College of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center. Dr. Kirtane completed a Hematology/Oncology Fellowship at the University of Washington and a Post-Doctoral Fellowship in Oncology at Fred Hutchinson Cancer Research Center. His clinical focus is on patients with head and neck-endocrine cancers. He works on the development of innovative cellular therapies for solid tumor cancers and is focused on increasing representation of underrepresented groups to clinical trials.



Arash Naghavi, MD, Associate Member – Radiation Oncology

Dr. Arash Naghavi is the Section Chief for the Sarcoma Radiotherapy Service at Moffitt Cancer Center. He has served on multiple editorial boards and contributed to the sarcoma consensus guidelines for the American Brachytherapy Society. Dr. Naghavi's primary research interest is in the integration of genomics and radiomics to personalize the treatment of soft tissue sarcoma with the goal of expanding our knowledge in radiation sensitivity, immunogenicity, and identifying predictors and potential targets, to optimize patient outcomes. This has led to over 70 peer-reviewed manuscripts identifying the relationships between pathologic response and outcome, and novel techniques to improve outcomes for retroperitoneal sarcoma and unresected sarcoma, culminating in the first personalized radiotherapy trial for sarcoma.



Abe Oraiqat, PhD, Assistant Member Physicist

Dr. Ibrahim Oraiqat is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Oraiqat received his PhD in Applied Physics, followed by a Medical Physics Postdoctoral fellowship in Radiation Oncology, from the University of Michigan, Ann Arbor. He most recently completed a Medical Physics Residency in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Oraiqat's clinical interest is in therapeutic medical physics with a focus on proton therapy, adaptive radiotherapy, and high dose rate (HDR) brachy-therapy. His research focus is the development and clinical translation of FLASH radiotherapy, novel dosimetry tools/methods, and novel imaging modalities for biological guidance in radiotherapy.

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$

$$dB = \dots$$



Lorraine Portelance, MD, Senior Member – Radiation Oncology

Dr. Portelance, received her medical degree and completed her Radiation Oncology residency at the Université de Montréal, followed by a fellowship in Radiation Oncology and Gynecologic Cancer Management at the Mallinckrodt Institute of Radiology. She currently serves as Vice Chair and Clinical Division Chief in the Department of Radiation Oncology at Moffitt Cancer Center.

An internationally recognized leader in gynecologic and gastrointestinal cancers, Dr. Portelance is a pioneer in MR-guided adaptive radiation therapy and has played a key role in advancing precision, organ-preserving treatments. She is an active clinical trialist, supporting national cooperative groups including NRG Oncology and Alliance for Clinical Trials in Oncology, and leads research focused on dose-escalated MR-guided radiation therapy for locally advanced rectal cancer.



Stephen Rosenberg, MD, Associate Member – Radiation Oncology

Dr. Stephen Rosenberg is an Associate Member in the Section of Thoracic Oncology of the Moffitt Cancer Center Department of Radiation Oncology and Director of Adaptive Radiotherapy. Dr. Rosenberg's clinical focus is the treatment of patients with thoracic malignancies and is interested in combining radiation with immunomodulatory drugs and targeted therapies to improve outcomes. Dr. Rosenberg also pursues research with a special focus on adaptive radiotherapy (MR or CT-based) and has reviewed scientific papers and abstracts of over 150 peers. He is interested in utilizing radiomics and genomics as part of his research efforts aimed at personalizing radiation therapy using novel approaches to improve local control of tumors and decrease side effects for patients.



Javier Torres-Roca, MD, Senior Member – Radiation Oncology

Dr. Javier F. Torres-Roca is a Senior Member in the Department of Radiation Oncology at Moffitt Cancer Center. He also serves as Professor of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Dr. Torres-Roca's research interests include the development of genomic strategies to personalize radiation therapy for individual patients. His clinical interest is in genitourinary malignancies. He is proficient in all the latest radiation technologies including IMRT, IGRT, VMAT and SBRT. He participates in numerous national committees including the NCCN National Guidelines, the RTOG Translational Research Program and others.



Stu Wasserman, MS, Chief Radiation Oncology Officer

Stuart Wasserman is a veteran medical physicist with more than three decades of experience leading clinical and operational programs in radiation oncology. He has served as Director of Clinical Physics at Moffitt Cancer Center since 2007 and subsequently held leadership roles as Division Administrator for Radiation Oncology and Chief Radiation Oncology Officer.

His prior experience includes serving as President of Radiophysics Associates, Inc., radiation safety officer roles at both Tampa General Hospital and Moffitt Cancer Center, and clinical positions at University Community Hospital and Memorial Sloan-Kettering Cancer Center, with a focus on brachytherapy. He is board certified in Therapeutic Radiological Physics by the American Board of Radiology and has held this certification since 1994.

MULTIDISCIPLINARY CLINIC

Genitourinary Tumor Board

As part of the Moffitt Cancer Center's goal to promote excellence and effectiveness in comprehensive cancer care, we will engage our audience through in-depth discussions with our multidisciplinary team, which includes program-specific radiation oncologists, surgeons, medical oncologists, pathologists, and radiologists. This approach enhances internal collaboration and transparency for our patients while also giving attendees insight into how we personalize and optimize patient treatments.



Daniel Grass, MD, PhD, Radiation Oncology

Dr. G. Daniel Grass is the Section Head of Genitourinary Oncology in the Department of Radiation Oncology and a professor at the University of South Florida Morsani College of Medicine. Dr. Grass employs multidisciplinary care models in prostate and bladder cancer to afford patients the opportunity to recognize all treatment options available so an informed decision can be made on the final approach. As a clinical-investigator, Dr. Grass's research interests are in personalizing patient radiation therapy by evaluating tumor-specific biology through various research tools and analyses, specifically in bladder cancer and rare genitourinary tumors, such as penile and small cell carcinoma of the bladder.



Julio Pow-Sang, MD, Chair, Genitourinary Oncology

Dr. Pow-Sang is a surgeon and Chair of the Department of Genitourinary Oncology at Moffitt Cancer Center. Dr. Pow-Sang is a principal investigator for numerous genitourinary cancer clinical trials and is a member of the prostate cancer guidelines panel for the National Comprehensive Cancer Network and member of the Florida Prostate Cancer Advisory Council. In addition, he is on the editorial board and a reviewer for many professional journals, as well as a member of professional medical societies in the U.S., Europe, and South America. A native of Peru, Dr. Pow-Sang received his medical degree from the Universidad Autonoma de Guadalajara in Mexico. He completed residencies in surgery and urology at the University of Miami School of Medicine and a fellowship in urological oncology at the University of Florida in Gainesville. Dr. Pow-Sang received a master's degree in business administration from the University of South Florida. Dr. Pow-Sang is fluent in English, Spanish, and French, and speaks conversational German and Italian. He has been named one of the Best Doctors in America since 1998.



Dr. Jon Chatzkel, MD, Medical Oncology, Genitourinary Oncology

Dr. Chatzkel is a clinical investigator with a research focus on novel therapeutic strategies for genitourinary cancers. His work explores novel combinations involving immune checkpoint inhibitors as well as antibody-drug conjugates and other targeted therapies. He is interested in the use of biomarkers to guide therapy -- particularly the use of circulating tumor DNA to evaluate for the presence of minimal residual disease and to personalize anti-cancer therapy.



Jasreman Dhillon, MD, Senior Member - GU Pathology

Dr. Dhillon received her medical training in India before moving to the United States. In the US she did her residency training in Pathology at Winthrop University Hospital, New York and three fellowships from MD Anderson Cancer Center in Surgical Pathology, Genitourinary (GU) Pathology and Cytopathology. Dr. Dhillon is a board-certified subspecialty trained pathologist currently working as an assistant member in the Department of Anatomic Pathology. She specializes in GU Pathology and Cytopathology.



Michael Poch, MD, Senior Member – Genitourinary Oncology

Dr. Poch's clinical interests include bladder, kidney and prostate cancer with an emphasis on minimally invasive surgery and robotics. He is a reviewer for numerous professional journals and is published in many peer-reviewed journals and has authored multiple book chapters on urologic oncology and robotics. He has lectured at national and international meetings. In addition, he currently sits on the National Comprehensive Cancer Network panel for prostate cancer early detection. Dr. Poch's research interests include health-related quality of life outcomes after oncologic surgery with a focus on post-operative body image and mental health assessments. Additional research interests include immunotherapy for bladder cancer, specifically evaluating the potential growth and expansion of tumor infiltrating lymphocytes. Dr. Poch is significantly involved in medical education at the University of South Florida and Moffitt Cancer Center. He is director of the Advanced Genitourinary Oncology elective for the medical school and is an integral part of the training for both the residents and Society for Urologic Oncology fellows.



Nainesh Parikh, MD, Associate Member, Diagnostic Imaging & Interventional Radiology

Dr. Parikh is a recognized expert in prostate artery embolization (PAE) and focuses clinically on benign prostatic hyperplasia, prostate cancer, kidney cancer, and primary and secondary liver cancers. He founded the PAE program at Moffitt Cancer Center in 2017 and serves as principal investigator for a clinical trial evaluating neoadjuvant PAE prior to definitive radiotherapy for prostate cancer. In addition to his clinical work, Dr. Parikh serves as Vice President and Chief Clinical Expansion and Partnership Officer at Moffitt, where he leads initiatives to expand access to MoffittCare through strategic partnerships. He previously served as Assistant Chief Medical Officer with responsibilities spanning finance, strategy, digital innovation, and clinical growth. Dr. Parikh earned his undergraduate degree from Columbia University and completed his MD and MBA at Tufts University.



Specializing In Radiation Oncology Design & Construction

“Experience the tru level of Excellence”



Tracy L. Donovan

Let our team of experts handle all aspects of your construction project so you can focus on what matters most, treating your patients. With our comprehensive management and attention to detail, we'll ensure a smooth process and successful outcome, allowing you to concentrate on delivering exceptional care.



📍 31119 US Hwy 19 N. Palm Harbor, FL 34684

☎ (727) 596-0408

@ Sales@truleveldesign.com

🌐 www.truleveldesign.com



CGC1523582

MULTIDISCIPLINARY CLINIC

Head and Neck Tumor Board



Jimmy Caudell, MD, PhD, Senior Member – Radiation Oncology

Dr. Caudell is a senior faculty member of Moffitt's Radiation Oncology Program and head of the department's Head and Neck program. Dr. Caudell emphasized his service to the community through his focus on the personalization of patient radiotherapy and directing research efforts towards prospective methods for controlling cancer and reducing toxicity. With national recognition for his treatment planning and clinical expertise, Dr. Caudell participates in numerous academic and sponsored investigations to evaluate novel radiosensitizers and radioprotectants, as well as use the technology to improve radiation delivery for head and neck cancers. Through additional outreach including industrial collaborations to enhance data management and workflow, Moffitt activity that has been key to the development of Head and Neck clinical pathways, and educational leadership that has fostered successful residents and new programs, Dr. Caudell sought to strengthen operations to support the field overall and benefit patients with comprehensive care.



Deepa Danan, MD, Vice Chair, Head and Neck Surgery

Dr. Deepa Danan is an Associate Member and Vice Chair of the Department of Head and Neck-Endocrine Oncology. She earned her MD from Columbia University College of Physicians and Surgeons, as well as an MBA from Columbia Business School and an MHA from the Columbia University Mailman School of Public Health. Dr. Danan completed her Otolaryngology-Head and Neck Surgery residency at the University of Virginia Health System, followed by a fellowship in Head and Neck Oncologic and Microvascular Surgery at the University of Miami. She joins Moffitt from the University of Florida, where she served as an Assistant Professor and Medical Director of the UF Health Shands ENT Clinic. Her clinical interests include cancers of the skin, oral cavity, oropharynx, larynx, thyroid, salivary glands, and neck, as well as select benign head and neck conditions. Her research focuses on outcome optimization in head and neck surgery, advances in thyroid and parathyroid surgery, and the impact of public health factors on cancer care delivery.



Guilherme Rabinowits, MD, Senior Member – Head and Neck Oncology

Dr. Guilherme Rabinowits is a Senior Member in the Department of Head and Neck-Endocrine Oncology. Dr. Rabinowits received his MD degree from Fundacao Tecnico-Educacional Souza Marques, Rio de Janeiro, Brazil. He completed an Internal Medicine residency at Lahey Clinic and Medical Center, Burlington, Massachusetts, followed by a Hematology/Medical Oncology Fellowship at the University of Louisville, Kentucky, where he also served as Chief Fellow. He then joined Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, as a Head and Neck Medical Oncologist until his move to Miami. Dr. Rabinowits joins us from the Miami Cancer Institute, Department of Hematology/Medical Oncology. Dr. Rabinowits's clinical interests focus on head and neck, endocrine, and skin cancer. In addition, he has extensive experience in clinical and translational research in developing novel therapies and clinically impactful biomarkers.

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$

$$dB = \dots$$



Juan Hernandez-Prera, MD, Associate Member – Head and Neck Pathology

Juan C. Hernandez-Prera, MD, FCAP, is an anatomic pathologist and Associate Member in the Department of Pathology at Moffitt Cancer Center in Tampa, Florida. He specializes in head and neck/endocrine pathology, with deep expertise in the clinical, histological, immunohistochemical, and molecular features of these tumors. Dr. Hernandez-Prera is a passionate educator and active contributor to the field. He is a frequent presenter at national and international conferences and has an extensive publication portfolio, including journal articles, book chapters, and textbooks.



Jack Farinhas, MD, Senior Member – Head and Neck Radiology

Dr. Joaquim Farinhas is an Associate Member in the Department of Diagnostic Imaging and Interventional Radiology. After receiving his MD from SUNY Upstate Medical University, Dr. Farinhas completed a Radiology Residency and a Diagnostic and Interventional Neuroradiology Fellowship at Montefiore Medical Center/Albert Einstein College of Medicine in New York. Following his fellowship, Dr. Farinhas was appointed Assistant Professor of Clinical Radiology at Montefiore Medical Center/Albert Einstein College of Medicine and was later promoted to Associate Professor. Dr. Farinhas joins us from Partners Imaging Centers in Sarasota, where he served as the Director of Neuroradiology. Dr. Farinhas's clinical interests focus on advanced imaging of brain, spine, head and neck cancers. He has conducted 3D medical imaging projects to assist in neurologic surgery planning. His research interests include novel uses of contrast media for MRI and CT, functional MRI, and enhanced CT of intracranial blood flow; he is also interested in research related to medical education.



ORGOVYX[®]
(relugolix) 120 mg tablets

**DIVE INTO
WHAT ORGOVYX
OFFERS.**



**LEARN MORE AT
ORGOVYXHCP.COM**



 is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.
ORGOVYX[®] and its associated logo are registered trademarks of Sumitomo Pharma Switzerland GmbH.
© 2024 Sumitomo Pharma Switzerland GmbH and Pfizer Inc. All rights reserved. ORG-US-0703-24 06/2024

$$\frac{dA}{dt} = k_1 A \left(1 - \frac{A}{S}\right)$$
$$\frac{dB}{dt} = k_1 A \left(\frac{A}{S}\right) \left(1 - \frac{B}{M_1}\right) - dB$$
$$\frac{dH}{dt} = k_2 H \left(1 - \frac{H}{M_2}\right)$$



THANK YOU >>>>>>

Thank you to all our attendees and sponsors for joining us at the Moffitt Radiation Oncology Conference. Your engagement, expertise and partnership are what make this gathering meaningful and impactful. We are grateful for your commitment to advancing innovation, collaboration and excellence in radiation oncology. Your support helps drive the progress that ultimately improves patient care and strengthens our shared mission to cure and prevent cancer.